Glenmark Pharmaceuticals valuation

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Enterprise multiples
Price multiples — at each FY-end close						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	43.37×	—	—	—	—
	6.17×	—	—	—	—
	3.66×	—	—	—	—
	31.10×	—	—	—	—
	3.59×	—	—	—	—
	13.29×	—	—	—	—
	15.25×	—	—	—	—
Yield
	2.3%	—	—	—	—
	3.2%	—	—	—	—
Reference — adjusted share basis
	₹2,300.00	—	—	—	—
	₹53.03	₹0.00	₹37.10	−₹53.21	₹13.37

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLENMARK₹2,300.00

Glenmark Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersDRREDDY LUPIN ALKEM BIOCON MANKIND LAURUSLABS FORTIS AUROPHARMAMcap ₹64,906 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

Multiples — ₹ Crore base 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Price Multiples — at each FY-end close
P/E	—	—	—	—	43.37
P/B	—	—	—	—	6.17
P/Sales	—	—	—	—	3.66
Price to Free Cash Flow	—	—	—	—	31.10
Enterprise Multiples
EV/Sales	—	—	—	—	3.59
EV/EBITDA	—	—	—	—	13.29
EV/EBIT	—	—	—	—	15.25
Yield
Earnings Yield %	—	—	—	—	2.31
FCF Yield %	—	—	—	—	3.22
Reference — adjusted share basis
Price (FY-end close, adj.)	—	—	—	—	2,300.00
EPS (adj.)	13.37	-53.21	37.10	0.00	53.03

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.